LONDON (ShareCast) - (ShareCast News) - Digital neuroscience technologies company IXICO announced on Wednesday that it has signed a new contract with an unnamed "top 15" global pharmaceutical company, utilising wrist worn activity sensors in a Phase II clinical trial for a neurological disorder.
The AIM-traded firm said it was its first commercial agreement using activity sensors to evaluate exploratory digital measures in early-phase clinical research, and followed a presentation of IXICO's approach to measuring sleep disturbances at the 'mobile devices for clinical trials in neurological diseases workshop' earlier this year at the Clinical Data Interchange Standards Consortium (CDISC) and the Critical Path Institute Coalition Against Major Diseases (CAMD) meetings.

It said the contract had a value of around £0.5m over a two year term, starting from September 2017.

IXICO would utilise its biosensor clinical trial capabilities, combined with its artificial intelligence data analytics algorithms, to measure activity and sleep disturbances from biosensor data collected from around 300 people.

"We are delighted to be deploying wearable biosensors and our proprietary algorithms to measure sleep disturbance in a commercial clinical trial," said IXICO CEO Giulio Cerroni.

"This is an excellent opportunity for IXICO to demonstrate how our biosensor services and technology, build upon our well-established expertise in providing regulatory compliant imaging endpoints in clinical trials, to support the process of developing new drugs to treat neurological diseases."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE